The recent failure of Pfizer's late-stage trial for Duchenne muscular dystrophy (DMD) gene therapy marks a significant setback for patients but opens the door for competitors like Sarepta Therapeutics. Pfizer’s…
Breaking News! Pfizer Inc. has just received FDA approval for Beqvez™, a groundbreaking gene therapy for adults with moderate to severe hemophilia B. Beqvez offers a life-changing treatment option for…
UPDATE: A New FDA approval has been released for Breyanzi. A request was submitted for approval for the expanded indication to include Relapsed and Refractory (R/R) Follicular Lymphoma and Marginal Zone…
Another new FDA approval expanding the indication for Abecma. Previously, it was approved only after failure of 4 or more prior lines of therapy. However, due to showing a progression-free…
Orchard's recent reveal of Lenmeldy's $4.25 million price tag has sparked conversations about the affordability of groundbreaking gene therapies. While Lenmeldy stands as the most expensive one-time gene therapy, it's…
Exciting advancements are on the horizon for Gene & Cell Therapies, particularly in the realm of treating hematologic and rare diseases. The anticipation surrounding the FDA approvals expected in 2024…